Erythropoietin and polyneuropathy in older persons

IntroductionRecent studies demonstrated that erythropoietin (EPO) have a number of non-erythropoietic effects including neuroprotection and vascular protection.MaterialsUsing data from a representative sample of older persons, we tested the hypothesis that EPO levels are correlated with peripheral nerve parameters (NVC and CMAP) assessed by surface ENG and with clinically diagnosed polyneuropathy. We selected 972 participants (aged 60–98 years) with complete data for the analyses.ResultsWe found a significant association between EPO and age-adjusted NCV and CMAP (for NCV: 0.57 ± 0.26; p = 0.03 and for CMAP: 0.54 ± 0.23; p = 0.02). In logistic regression models adjusting for age, sex and multiple potential confounders, higher EPO levels were associated with a significantly lower probability of having a clinical diagnosis of polyneuropathy (OR = 0.43; 95% CI: 0.22–0.84).DiscussionThese findings suggest that EPO is implicated in the pathogenesis of polyneuropathy in older persons. Whether low EPO is a risk factor for polyneuropathy should be tested in future longitudinal analyses.